Sanara MedTech’s (SMTI) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Sanara MedTech (NASDAQ:SMTI) in a report issued on Wednesday,Benzinga reports. They currently have a $44.00 price target on the stock. Cantor Fitzgerald also issued estimates for Sanara MedTech’s FY2025 earnings at ($1.09) EPS.

Separately, HC Wainwright began coverage on Sanara MedTech in a research report on Monday, December 23rd. They set a “buy” rating and a $50.00 price objective for the company.

Sanara MedTech Stock Down 2.6 %

NASDAQ:SMTI opened at $37.12 on Wednesday. Sanara MedTech has a 1 year low of $26.00 and a 1 year high of $40.75. The stock has a 50-day moving average price of $34.70 and a two-hundred day moving average price of $32.87. The stock has a market cap of $324.43 million, a price-to-earnings ratio of -37.49 and a beta of 1.55. The company has a current ratio of 2.23, a quick ratio of 2.02 and a debt-to-equity ratio of 0.76.

Sanara MedTech (NASDAQ:SMTI) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.28. The business had revenue of $21.67 million during the quarter. Sanara MedTech had a negative return on equity of 19.86% and a negative net margin of 10.71%. During the same quarter in the prior year, the firm posted ($0.13) earnings per share. As a group, equities analysts expect that Sanara MedTech will post -1.33 earnings per share for the current year.

Institutional Investors Weigh In On Sanara MedTech

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. grew its holdings in shares of Sanara MedTech by 127.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,058 shares of the company’s stock valued at $123,000 after acquiring an additional 2,272 shares in the last quarter. Barclays PLC grew its stake in Sanara MedTech by 323.0% in the third quarter. Barclays PLC now owns 5,731 shares of the company’s stock valued at $174,000 after purchasing an additional 4,376 shares in the last quarter. Fifth Third Bancorp acquired a new position in shares of Sanara MedTech during the 4th quarter worth approximately $898,000. State Street Corp raised its stake in shares of Sanara MedTech by 9.2% during the 3rd quarter. State Street Corp now owns 58,688 shares of the company’s stock worth $1,775,000 after purchasing an additional 4,932 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Sanara MedTech by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 88,271 shares of the company’s stock valued at $2,670,000 after buying an additional 3,755 shares during the last quarter. 8.10% of the stock is owned by institutional investors.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.